Access
To read this story in full you will need to login or make a payment (see right).
Books and Arts
Nature 453, 855-856 (12 June 2008) | doi:10.1038/453855a; Published online 11 June 2008
Open Innovation Challenges
-
Efficient Chromosome Doubling: Plant Cell Division
The Seeker is looking for an efficient chromosome doubling method in plants and in particular, metho...
-
Fast Growth of Transformed Soybean Shoots
A method for accelerating growth of soybean shoots is desired.
- More Challenges
- Powered by:
nature jobs
Research Fellows in Pluripotent Stem Cell Technology
- The University of Nottingham
- Nottingham, UK
Research Fellows in Pluripotent Stem Cell Technology
- The University of Nottingham
- Nottingham, UK
A prescription for public health
Merrill Goozner1
Abstract
Will high drug prices and a lack of new medicines force the pharmaceutical industry to restructure and take a more personalized approach to research, asks Merrill Goozner.
BOOK REVIEWED-Reasonable Rx: Solving the Drug Price Crisis
by Stan Finkelstein & Peter Temin
FT Press: 2008. 208 pp. $27.99
Pharmaceutical executives will find nothing reasonable in the provocative view offered in Reasonable Rx. In this discussion of prescription drug (or Rx) policy, medical researcher Stan Finkelstein and economist Peter Temin of the Massachusetts Institute of Technology propose the break-up of pharmaceutical companies into two separate entities: one devoted to research and development (R&D) and the other to manufacturing and marketing.
To read this story in full you will need to login or make a payment (see right).
